|1.||Kurtz, Caroline B: 15 articles (01/2015 - 09/2007)|
|2.||Johnston, Jeffrey M: 14 articles (01/2015 - 09/2007)|
|3.||Currie, Mark G: 14 articles (01/2015 - 09/2007)|
|4.||Lembo, Anthony J: 8 articles (04/2015 - 01/2009)|
|5.||Lavins, Bernard J: 7 articles (01/2015 - 12/2010)|
|6.||Shiff, Steven J: 6 articles (01/2015 - 08/2011)|
|7.||MacDougall, James E: 6 articles (04/2014 - 01/2009)|
|8.||Hannig, Gerhard: 5 articles (01/2014 - 05/2010)|
|9.||Jia, Xinwei D: 4 articles (01/2015 - 08/2011)|
|10.||Currie, M G: 4 articles (12/2014 - 03/2010)|
01/01/2015 - "Once-daily linaclotide (145 and 290 μg) significantly improved bowel and abdominal symptoms in chronic idiopathic constipation patients with moderate-to-severe baseline abdominal bloating; in particular, linaclotide significantly improved abdominal bloating compared to placebo, an important finding given the lack of agents available to treat abdominal bloating in chronic idiopathic constipation patients. "
10/01/2013 - "Linaclotide is superior to placebo for the treatment of both IBS-C and Chronic Idiopathic Constipation. "
05/01/2011 - "Linaclotide appears to be a well-tolerated and effective agent for many patients with chronic constipation and IBS-C. "
11/01/2013 - "The efficacy of linaclotide has been studied in both CIC and constipation-predominant IBS (IBS-C). "
03/01/2010 - "We assessed the safety and efficacy of a range of linaclotide doses in patients with chronic constipation. "
|2.||Abdominal Pain (Pain, Abdominal)
03/01/2014 - "Most linaclotide-treated IBS-C patients who were FDA non-responders reported some improvement in abdominal pain and stool frequency, and global relief/satisfaction. "
10/01/2013 - "Data from Phase II and III clinical trials demonstrated that linaclotide seems to produce a statistically significant increase in stool frequency, improved straining, decreased abdominal pain and discomfort."
01/01/2013 - "A significantly greater proportion of linaclotide-treated vs. placebo-treated patients were 12-week abdominal pain/discomfort responders (Trial 31: 54.8% vs. 41.8%; Trial 302: 54.1% vs. 38.5%; P < 0.001) and IBS degree-of-relief responders (Trial 31: 37.0% vs. 18.5%; Trial 302: 39.4% vs. 16.6%; P < 0.0001). "
12/01/2013 - "During 26 weeks of linaclotide administration, a significantly greater percentage of patients (70%) had at least a 30% reduction in abdominal pain compared with patients given placebo (50%). "
01/01/2013 - "Linaclotide treatment significantly improved abdominal pain/discomfort and degree-of-relief of IBS-C symptoms compared with placebo over 12 and 26 weeks. "
|3.||Irritable Bowel Syndrome (Syndrome, Irritable Bowel)
09/01/2013 - "Linaclotide for treatment of irritable bowel syndrome--the view of European regulators."
12/01/2011 - "To review the pharmacology, pharmacokinetics, efficacy, and safety of linaclotide for irritable bowel syndrome (IBS). "
12/01/2011 - "Linaclotide: a novel approach to the treatment of irritable bowel syndrome."
07/01/2013 - "To conclude, linaclotide has a safety and efficacy profile that, from a clinical perspective, warrants its use for patients meeting irritable bowel syndrome and constipation criteria, with significant symptoms that cannot be relieved with other less specific measures. "
11/01/2013 - "Linaclotide: new mechanisms and new promise for treatment in constipation and irritable bowel syndrome."
04/01/2014 - "Linaclotide is moderately effective in improving symptoms of IBS-C with diarrhea being the major side effect. "
11/01/2012 - "Overall, both linaclotide trials found the medication to be safe in terms of serious adverse events, though the secretagogue mechanism of action led to diarrhea in approximately one in five subjects. "
08/11/2011 - "The incidence of adverse events was similar among all study groups, with the exception of diarrhea, which led to discontinuation of treatment in 4.2% of patients in both linaclotide groups. "
01/01/2015 - "Diarrhea was reported in 6% and 17% of linaclotide 145 and 290 μg patients, respectively, and 2% of placebo patients. "
07/01/2014 - "The most common adverse effect of linaclotide is diarrhea, which was reported in 16-20% of clinical trial participants. "
10/01/2008 - "Highly promising results have been obtained in the treatment of constipation with prokinetics such as prucalopride and with novel laxatives such as linaclotide, as well as with techniques that continue to be shown to be effective such as anorectal biofeedback, which is also highly useful in patients with fecal incontinence. "
|3.||Guanylate Cyclase (Guanylyl Cyclase)
|4.||enterotoxin receptor (guanylyl cyclase C)
|9.||5'-Guanylic Acid (GMP)
|10.||p38 Mitogen-Activated Protein Kinases
|1.||Psychology Biofeedback (Biofeedback)
|3.||Drug Therapy (Chemotherapy)